Benlysta

Sandoz has secured ex-China commercialization rights to an initial biosimilar portfolio under a collaboration worth up to $322 million, while Henlius retains responsibility for development, manufacturing and supply. Representative image.

Sandoz-Henlius $322m biosimilar deal starts with three blockbusters and could expand to 10 assets

by Pallavi Madhiraju
August 22, 2026
0 Comments

Sandoz gains ex-China commercialization rights to an initial biosimilar portfolio while Henlius retains development, manufacturing and supply responsibilities under a collaboration worth up to $322 million.

$Fate Therapeutics has dosed the first participant in the Phase 2 RECLAIM-LN study of FT819, its off-the-shelf CD19-directed CAR T-cell therapy being evaluated for refractory moderate-to-severe lupus nephritis. Representative image.$

Pharma & Biotech

Fate Therapeutics starts potentially registrational FT819 trial in lupus nephritis

by Venkatesh B
August 15, 2026
0 Comments

Fate Therapeutics has treated the first participant in RECLAIM-LN, a Phase 2 study evaluating its off-the-shelf CD19-directed CAR T-cell candidate FT819 in people with refractory moderate-to-severe lupus nephritis. The company disclosed the trial initiation on August 14, 2026, saying the first participant received FT819 in an outpatient setting and was discharged on the same day.